肝癌分子靶向药物治疗影像学疗效评价进展
|
摘要
近年来随着对肝癌分子机制深入研究,分子靶向治疗成为中晚期肝癌的治疗热点。治疗后肝癌病灶除瘤体直径变化外,常因内部癌细胞坏死活性降低,在CT/MRI表现为低密度的改变,给临床疗效评价带来了困难与挑战,而准确的疗效评价对指导临床治疗非常关键,本文就总结近些年来相关文献报道,对临床常用影像学进行肝癌分子靶向药物治疗的影像学疗效评价进展进行以下分析,为广大医学工作者临床诊疗提供理论依据。
In recent years, molecular targeted therapy has become a hot topic in the treatment of advanced hepatocellular carcinoma(HCC). In addition to the changes in tumor diameter, the lesions of hepatocellular carcinoma after treatment are often due to the reduced necrotic activity of internal cancer cells, which is manifested as the change of low density in CT/MRI, which brings difficulties and challenges to clinical efficacy evaluation, and accurate efficacy evaluation is very critical to guiding clinical treatment. This paper summarizes the relevant literature reports in recent years, and analyzes the progress of imaging efficacy evaluation of molecular targeted drug therapy for hepatocellular carcinoma in common clinical imaging, so as to provide theoretical basis for the clinical diagnosis and treatment of medical workers.
In recent years, molecular targeted therapy has become a hot topic in the treatment of advanced hepatocellular carcinoma(HCC). In addition to the changes in tumor diameter, the lesions of hepatocellular carcinoma after treatment are often due to the reduced necrotic activity of internal cancer cells, which is manifested as the change of low density in CT/MRI, which brings difficulties and challenges to clinical efficacy evaluation, and accurate efficacy evaluation is very critical to guiding clinical treatment. This paper summarizes the relevant literature reports in recent years, and analyzes the progress of imaging efficacy evaluation of molecular targeted drug therapy for hepatocellular carcinoma in common clinical imaging, so as to provide theoretical basis for the clinical diagnosis and treatment of medical workers.
引文
[1]岳新建.DWI对晚期肝细胞肝癌患者分子靶向药物治疗的疗效评估[J].中国中西医结合影像学杂志,2016,14(5):514-516.
[2]岳倩倩,王新怡.肝细胞肝癌分子靶向治疗的影像学评价进展[J].中华临床医师杂志(电子版),2016, 10(9):1312-1316.
[3]张健,邵初晓.原发性肝癌早期诊断的研究进展[J].中华肝胆外科杂志,2014, 20(9):689-693.
[4]张金坤,王燕燕.原发性肝癌发生机制及其治疗的研究进展[J].中国药房,2015,26(29):4171-4173.
[5] Miller AB, Hoogstraten B, Staquet M, etal.Reporting results of cancer treatmen[J]. Cancer, 1981, 47:207-214.
[6]李虎子,贾英杰,孔凡铭,等.改良RECIST标准更适用经TACE治疗的肝癌患者的预后评价[J].介入放射学杂志,2016, 25(1):29-33.
[7]赵丽,赵振华,杨建峰,等.动态增强MRI定量参数对肝癌诊断和疗效评估的研究进展[J].中华医学杂志,2015, 95(43):3557-3560.
[8]龙莉玲,彭鹏,黄仲奎,等.原发性肝癌的早期影像学诊断[J].中华肝脏病杂志,2017, 25(5):329-332.
[9]袁筑慧,王洋,郑加生等.肝癌治疗疗效影像学评价标准研究现状与进展[J].北京医学,2017, 39(9):947-949.
[10]陈立军,杨仁杰,朱林忠,等.原发性肝癌介入术中肝动脉-门静脉瘘的影像学特点及治疗[J].中国肿瘤临床,2015,42(11):570-575.
[11]秦建民,盛霞.分子靶向纳米技术在肝细胞癌诊断与治疗中的应用及意义[J].中华肝胆外科杂志,2017,23(4):281-285.
[12]贾晨.TACE联合热学疗法治疗肝癌的临床疗效分析[J].实用癌症杂志,2015, 30(3):423-425,441.
[2]岳倩倩,王新怡.肝细胞肝癌分子靶向治疗的影像学评价进展[J].中华临床医师杂志(电子版),2016, 10(9):1312-1316.
[3]张健,邵初晓.原发性肝癌早期诊断的研究进展[J].中华肝胆外科杂志,2014, 20(9):689-693.
[4]张金坤,王燕燕.原发性肝癌发生机制及其治疗的研究进展[J].中国药房,2015,26(29):4171-4173.
[5] Miller AB, Hoogstraten B, Staquet M, etal.Reporting results of cancer treatmen[J]. Cancer, 1981, 47:207-214.
[6]李虎子,贾英杰,孔凡铭,等.改良RECIST标准更适用经TACE治疗的肝癌患者的预后评价[J].介入放射学杂志,2016, 25(1):29-33.
[7]赵丽,赵振华,杨建峰,等.动态增强MRI定量参数对肝癌诊断和疗效评估的研究进展[J].中华医学杂志,2015, 95(43):3557-3560.
[8]龙莉玲,彭鹏,黄仲奎,等.原发性肝癌的早期影像学诊断[J].中华肝脏病杂志,2017, 25(5):329-332.
[9]袁筑慧,王洋,郑加生等.肝癌治疗疗效影像学评价标准研究现状与进展[J].北京医学,2017, 39(9):947-949.
[10]陈立军,杨仁杰,朱林忠,等.原发性肝癌介入术中肝动脉-门静脉瘘的影像学特点及治疗[J].中国肿瘤临床,2015,42(11):570-575.
[11]秦建民,盛霞.分子靶向纳米技术在肝细胞癌诊断与治疗中的应用及意义[J].中华肝胆外科杂志,2017,23(4):281-285.
[12]贾晨.TACE联合热学疗法治疗肝癌的临床疗效分析[J].实用癌症杂志,2015, 30(3):423-425,441.